Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
Publication
, Journal Article
Khuntia, D; Mehta, M
Published in: Expert Rev Anticancer Ther
December 2004
Despite recent advances in both technology and molecular targeting, little progress has been made in the management of most malignancies of the brain, especially brain metastases. In an effort to increase the therapeutic ratio of external beam radiation treatments, radiosensitizers and enhancers have been investigated. Motexafin gadolinium is a new drug with radioenhancing properties and a unique mechanism of action that may increase the therapeutic index of whole brain radiotherapy for patients with brain metastases. The rationale for the use of this drug as well as its current and future role as a radiation enhancer in the management of brain tumors is reviewed.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Expert Rev Anticancer Ther
DOI
EISSN
1744-8328
Publication Date
December 2004
Volume
4
Issue
6
Start / End Page
981 / 989
Location
England
Related Subject Headings
- Radiation-Sensitizing Agents
- Oncology & Carcinogenesis
- Metalloporphyrins
- Humans
- Cranial Irradiation
- Combined Modality Therapy
- Brain Neoplasms
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Khuntia, D., & Mehta, M. (2004). Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther, 4(6), 981–989. https://doi.org/10.1586/14737140.4.6.981
Khuntia, Deepak, and Minesh Mehta. “Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.” Expert Rev Anticancer Ther 4, no. 6 (December 2004): 981–89. https://doi.org/10.1586/14737140.4.6.981.
Khuntia D, Mehta M. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther. 2004 Dec;4(6):981–9.
Khuntia, Deepak, and Minesh Mehta. “Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.” Expert Rev Anticancer Ther, vol. 4, no. 6, Dec. 2004, pp. 981–89. Pubmed, doi:10.1586/14737140.4.6.981.
Khuntia D, Mehta M. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther. 2004 Dec;4(6):981–989.
Published In
Expert Rev Anticancer Ther
DOI
EISSN
1744-8328
Publication Date
December 2004
Volume
4
Issue
6
Start / End Page
981 / 989
Location
England
Related Subject Headings
- Radiation-Sensitizing Agents
- Oncology & Carcinogenesis
- Metalloporphyrins
- Humans
- Cranial Irradiation
- Combined Modality Therapy
- Brain Neoplasms
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis